Pharvaris N.V. (NASDAQ:PHVS - Get Free Report)'s share price hit a new 52-week high during trading on Saturday . The company traded as high as $25.76 and last traded at $25.12, with a volume of 155746 shares traded. The stock had previously closed at $19.83.
Analyst Ratings Changes
A number of research firms have commented on PHVS. Cantor Fitzgerald reduced their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Guggenheim began coverage on Pharvaris in a research report on Wednesday, June 11th. They issued a "buy" rating and a $32.00 target price on the stock. Finally, Wedbush reaffirmed an "outperform" rating and issued a $27.00 price objective on shares of Pharvaris in a research note on Thursday, June 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pharvaris has an average rating of "Buy" and an average target price of $36.20.
View Our Latest Stock Report on PHVS
Pharvaris Price Performance
The stock has a 50 day moving average price of $17.37 and a two-hundred day moving average price of $16.71. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -7.64 and a beta of -2.82.
Pharvaris (NASDAQ:PHVS - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). As a group, research analysts expect that Pharvaris N.V. will post -2.71 earnings per share for the current fiscal year.
Institutional Trading of Pharvaris
A number of institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its stake in Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after acquiring an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in Pharvaris during the 4th quarter valued at approximately $64,000. KLP Kapitalforvaltning AS purchased a new stake in Pharvaris during the 4th quarter valued at approximately $111,000. Point72 Asset Management L.P. purchased a new stake in Pharvaris during the 4th quarter valued at approximately $152,000. Finally, Legal & General Group Plc raised its stake in Pharvaris by 11.2% during the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after acquiring an additional 994 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Further Reading
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
